• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃及消除丙型肝炎病毒的宏伟战略:案例研究。

Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study.

机构信息

Westchester Medical Center/New York Medical College, NY USA.

Yale School of Medicine, New Haven, CT, USA.

出版信息

Glob Health Sci Pract. 2021 Mar 31;9(1):187-200. doi: 10.9745/GHSP-D-20-00234.

DOI:10.9745/GHSP-D-20-00234
PMID:33795369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8087425/
Abstract

INTRODUCTION

Chronic hepatitis C virus (HCV) infection is a major public health problem in many low- and middle-income countries. In 2015, Egypt's HCV infection prevalence of 7% among adults was among the highest in the world and accounted for 7.6% of the country's mortality. In 2014, Egypt embarked on an aggressive screening and treatment program that evolved into a national strategy to eliminate HCV as a public health threat by 2021.

METHODS

In this qualitative case study, we analyzed Egypt's HCV control strategy using the Kingdon framework to understand how the problem, policy, and political streams merged to create an opportunity to achieve an ambitious elimination goal. We describe key aspects of the implementation, identify lessons learned, and provide recommendations for other low- and middle-income countries aiming to eliminate HCV.

RESULTS

Between 2014 and 2020, Egypt screened more than 50 million and treated more than 4 million residents for HCV. Five key elements contributed to Egypt's successful HCV elimination program: (1) sufficient and reliable epidemiologic data to quantify and monitor public health threats; (2) a robust public health care infrastructure; (3) inclusive care that reached all sectors of society; (4) increased health care spending; and (5) innovative scientific research and use of information technology.

CONCLUSION

Egypt conducted a successful HCV screening program that covered more than 50 million residents and treated more than 4 million. It is poised to be the first country in the world to eliminate HCV within its borders. The lessons learned from this experience can inform the elimination plans of other low- and middle-income countries with high HCV burden.

摘要

简介

慢性丙型肝炎病毒 (HCV) 感染是许多低收入和中等收入国家的一个主要公共卫生问题。2015 年,埃及成年人 HCV 感染率为 7%,居世界首位,占该国死亡率的 7.6%。2014 年,埃及启动了一项积极的筛查和治疗计划,该计划后来演变为一项国家战略,旨在到 2021 年消除 HCV 对公共卫生的威胁。

方法

在这项定性案例研究中,我们使用金登框架分析了埃及的 HCV 控制策略,以了解问题、政策和政治流是如何融合在一起,为实现一个雄心勃勃的消除目标创造机会的。我们描述了实施的关键方面,确定了经验教训,并为其他旨在消除 HCV 的低收入和中等收入国家提供了建议。

结果

2014 年至 2020 年间,埃及对 5000 多万居民进行了 HCV 筛查,并对 400 多万居民进行了 HCV 治疗。埃及 HCV 消除计划的成功有五个关键因素:(1)有足够和可靠的流行病学数据来量化和监测公共卫生威胁;(2)强大的公共卫生保健基础设施;(3)包容各个社会阶层的关怀;(4)增加医疗保健支出;(5)创新性的科学研究和信息技术的使用。

结论

埃及开展了一项成功的 HCV 筛查计划,覆盖了 5000 多万居民,并对 400 多万人进行了治疗。埃及有望成为世界上第一个在其境内消除 HCV 的国家。从这一经验中吸取的教训可以为其他 HCV 负担高的低收入和中等收入国家的消除计划提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/8321657639fe/GH-GHSP210028F003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/3ca7eedb678d/GH-GHSP210028F004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/f8e6ab59f2a1/GH-GHSP210028F001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/6ad6d28b6c79/GH-GHSP210028F005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/dc7e1443cc35/GH-GHSP210028F002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/17d44af814ed/GH-GHSP210028F006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/8321657639fe/GH-GHSP210028F003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/3ca7eedb678d/GH-GHSP210028F004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/f8e6ab59f2a1/GH-GHSP210028F001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/6ad6d28b6c79/GH-GHSP210028F005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/dc7e1443cc35/GH-GHSP210028F002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/17d44af814ed/GH-GHSP210028F006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e62/8087425/8321657639fe/GH-GHSP210028F003.jpg

相似文献

1
Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study.埃及消除丙型肝炎病毒的宏伟战略:案例研究。
Glob Health Sci Pract. 2021 Mar 31;9(1):187-200. doi: 10.9745/GHSP-D-20-00234.
2
Evidence for the elimination of viral hepatitis B and C in Egypt: Results of a nationwide survey in 2022.埃及消除乙型和丙型病毒性肝炎的证据:2022年全国性调查结果
Liver Int. 2024 Apr;44(4):955-965. doi: 10.1111/liv.15843. Epub 2024 Jan 30.
3
Securing sustainable funding for viral hepatitis elimination plans.为消除病毒性肝炎计划确保可持续资金。
Liver Int. 2020 Feb;40(2):260-270. doi: 10.1111/liv.14282. Epub 2019 Dec 5.
4
An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.埃及消除丙型肝炎感染的教育、检测与治疗模式:73个村庄的可行性与有效性
J Hepatol. 2020 Apr;72(4):658-669. doi: 10.1016/j.jhep.2019.11.004. Epub 2019 Nov 14.
5
Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.迈向丙型肝炎病毒消除:埃及的经验、成就和局限。
World J Gastroenterol. 2018 Oct 14;24(38):4330-4340. doi: 10.3748/wjg.v24.i38.4330.
6
Lessons of "what-if" thirty years ago in population policy.三十年前人口政策中“如果……将会怎样”的教训。
Dirasat Sukkaniyah. 1984 Apr-Jun;11(69):3-18, [17-21].
7
Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt.从 5700 万公民的筛查中发现并治疗了 400 万患者:从埃及消除丙型肝炎的未来策略。
Expert Rev Anti Infect Ther. 2020 Jul;18(7):637-642. doi: 10.1080/14787210.2020.1758065. Epub 2020 Apr 23.
8
Advancing Hepatitis C Elimination in Africa: Insights from Egypt.推进非洲丙型肝炎消除工作:来自埃及的见解
Hepat Med. 2024 Jun 4;16:37-44. doi: 10.2147/HMER.S470344. eCollection 2024.
9
Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.摩尔多瓦消除丙型肝炎是可行且具有成本效益的:一项建模研究。
J Infect Dis. 2023 Sep 13;228(Suppl 3):S189-S197. doi: 10.1093/infdis/jiad138.
10
Case study of hepatitis C virus control in Egypt: impact of access program.埃及丙型肝炎病毒控制案例研究:获得方案的影响。
Antivir Ther. 2022 Apr;27(2):13596535211067592. doi: 10.1177/13596535211067592.

引用本文的文献

1
Global disparities in access to hepatitis C medicines before and during the early phase of the COVID-19 pandemic: an ARIMA-based interrupted time series analysis.2019年冠状病毒病大流行早期之前及期间丙型肝炎药物获取情况的全球差异:基于自回归积分滑动平均模型的中断时间序列分析
BMJ Public Health. 2025 Jun 25;3(1):e001340. doi: 10.1136/bmjph-2024-001340. eCollection 2025.
2
Assessing user experience with the Bioline™ HCV point-of-care test in primary healthcare settings: a mixed-methods study.在基层医疗环境中评估用户对Bioline™丙型肝炎即时检测的体验:一项混合方法研究。
BMC Health Serv Res. 2025 Apr 1;25(1):484. doi: 10.1186/s12913-025-12634-8.
3

本文引用的文献

1
Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles.埃及丙型肝炎慢性治疗中大规模治疗期间设施绩效评估:促进因素和障碍。
J Infect Public Health. 2020 Sep;13(9):1322-1329. doi: 10.1016/j.jiph.2020.05.008. Epub 2020 May 27.
2
Screening and Treatment Program to Eliminate Hepatitis C in Egypt.埃及消除丙型肝炎的筛查与治疗项目。
N Engl J Med. 2020 Mar 19;382(12):1166-1174. doi: 10.1056/NEJMsr1912628.
3
Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program.
Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.
消除 HCV 感染:近年流行病学发现、障碍及未来策略。
Viruses. 2024 Nov 19;16(11):1792. doi: 10.3390/v16111792.
4
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.用于治疗丙型肝炎病毒的长效技术的偏好与可行性:对不同低收入和中等收入国家患者的一项调查
J Viral Hepat. 2025 Apr;32(4):e14031. doi: 10.1111/jvh.14031. Epub 2024 Nov 15.
5
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.重视药品和其他卫生技术的社会影响:当前最佳实践用户指南。
Forum Health Econ Policy. 2024 Nov 8;27(1):29-116. doi: 10.1515/fhep-2024-0014. eCollection 2024 Jun 1.
6
Liver Cancer and Risk Factors in the MENA Region: Epidemiology and Temporal Trends Based on the 2019 Global Burden of Disease Data.中东和北非地区的肝癌与风险因素:基于 2019 年全球疾病负担数据的流行病学和时间趋势。
Cancer Control. 2024 Jan-Dec;31:10732748241297346. doi: 10.1177/10732748241297346.
7
Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C.竞争市场中的替代药物创新模式:开发丙型肝炎新药的协作方法
Trop Med Infect Dis. 2024 Oct 8;9(10):233. doi: 10.3390/tropicalmed9100233.
8
Hepatitis C Elimination in Egypt: Story of Success.埃及消除丙型肝炎:成功故事
Pathogens. 2024 Aug 12;13(8):681. doi: 10.3390/pathogens13080681.
9
The Egyptian journey from having the highest prevalence of hepatitis C virus to being the first to achieve "gold tier" in conquering the disease.埃及从丙型肝炎病毒患病率最高,到率先在攻克该疾病方面达到“黄金级别”的历程。
Proc (Bayl Univ Med Cent). 2024 Jul 22;37(5):877-883. doi: 10.1080/08998280.2024.2379185. eCollection 2024.
10
Assessment of hepatitis c core antigen in epithelial salivary gland neoplasms (ex-vivo study).评估上皮性唾液腺肿瘤中的丙型肝炎核心抗原(离体研究)。
BMC Oral Health. 2024 Aug 6;24(1):900. doi: 10.1186/s12903-024-04632-9.
埃及的丙型肝炎病毒:来自全球最大国家项目的中期报告。
Clin Liver Dis (Hoboken). 2020 Jan 29;14(6):203-206. doi: 10.1002/cld.868. eCollection 2019 Dec.
4
One step closer to elimination of hepatitis C in Egypt.埃及在消除丙型肝炎方面又迈进了一步。
Lancet Gastroenterol Hepatol. 2018 Oct;3(10):665. doi: 10.1016/S2468-1253(18)30268-1.
5
An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.埃及消除丙型肝炎感染的教育、检测和治疗方案:基于社区的示范项目。
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):778-789. doi: 10.1016/S2468-1253(18)30139-0. Epub 2018 Jul 18.
6
Assessing the level of knowledge and available sources of information about hepatitis C infection among HCV-infected Egyptians.评估埃及 HCV 感染者对丙型肝炎感染的了解程度和可用信息来源。
BMC Public Health. 2018 Jun 18;18(1):747. doi: 10.1186/s12889-018-5672-6.
7
Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.规划和优先考虑资源有限国家的 HCV 患者直接作用抗病毒治疗:来自埃及经验的教训。
J Hepatol. 2018 Apr;68(4):691-698. doi: 10.1016/j.jhep.2017.11.034. Epub 2017 Dec 6.
8
Hepatitis C infection in Egypt: prevalence, impact and management strategies.埃及的丙型肝炎感染:患病率、影响及管理策略。
Hepat Med. 2017 May 15;9:17-25. doi: 10.2147/HMER.S113681. eCollection 2017.
9
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.2015 年全球丙型肝炎病毒感染的流行率和基因型分布:一项建模研究。
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16.
10
Hepatitis C in Egypt - past, present, and future.埃及的丙型肝炎——过去、现在与未来
Int J Gen Med. 2016 Dec 20;10:1-6. doi: 10.2147/IJGM.S119301. eCollection 2017.